Once-daily indacaterol 75 μg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients’ perceived onset of effect

BACKGROUND: Indacaterol 75 μg once daily is a long-acting β(2) agonist approved for maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD). The purpose of this study was to evaluate patients’ perception of onset of effect with a single dose. METHODS: In th...

Descripción completa

Detalles Bibliográficos
Autores principales: Siler, Thomas M, LaForce, Craig F, Kianifard, Farid, Williams, James, Spangenthal, Selwyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159068/
https://www.ncbi.nlm.nih.gov/pubmed/25214778
http://dx.doi.org/10.2147/COPD.S67356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159068/
https://www.ncbi.nlm.nih.gov/pubmed/25214778
http://dx.doi.org/10.2147/COPD.S67356

Ejemplares similares